Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis

Dario Roccatello; Roberta Fenoglio; Simone Baldovino; Carla Naretto; Michela Ferro; Antonella Barreca; Daniela Rossi; Savino Sciascia

doi:10.1016/j.autrev.2020.102622

Towards a novel target therapy for renal diseases related to plasma cell dyscrasias: The example of AL amyloidosis

Autoimmun Rev. 2020 Sep;19(9):102622. doi: 10.1016/j.autrev.2020.102622. Epub 2020 Jul 12.

Authors

Dario Roccatello¹, Roberta Fenoglio², Simone Baldovino², Carla Naretto², Michela Ferro², Antonella Barreca³, Daniela Rossi², Savino Sciascia²

Affiliations

¹ Nephrology and Dialysis Unit-CMID, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital of Turin, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy. Electronic address: dario.roccatello@unito.it.
² Nephrology and Dialysis Unit-CMID, Center of Research of Immunopathology and Rare Diseases, Coordinating Center of the Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hospital of Turin, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
³ Pathology Division, Department of Oncology, University of Turin, Italy.

PMID: 32663622
DOI: 10.1016/j.autrev.2020.102622

Abstract

Immunoglobulin light chain amyloidosis is a rare systemic disease caused by monoclonal light chains (LCs) depositing in tissue as insoluble fibrils resulting in irreversible damage of vital organs. The mechanisms involved in aggregation and deposition of LCs are not fully understood, but CD138/38 plasma cells are undoubtedly involved in monoclonal LC production. We are reporting favorable effects on AL amyloidosis patients with renal involvement using the anti-CD38 monoclonal antibody Daratumumab. We speculate that research for the near future should be devoted to design similar therapeutic approaches for other diseases attributable to a plasma cell dyscrasia.

Keywords: AL amyloidosis; Anti-CD38 MoAb; Daratumumab; Plasma cell dyscrasia.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Humans
Immunoglobulin Light Chains
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Immunoglobulin Light-chain Amyloidosis / pathology
Kidney / pathology
Kidney Diseases / drug therapy*
Kidney Diseases / pathology
Paraproteinemias / drug therapy*
Paraproteinemias / pathology

Substances

Antibodies, Monoclonal
Immunoglobulin Light Chains
daratumumab